Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Francesca Matilde Schipilliti; Denise Drittone; Federica Mazzuca; Daniele La Forgia; Deniz Can Guven; Alessandro Rizzo

doi:10.1016/j.heliyon.2024.e28385

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Heliyon. 2024 Mar 22;10(7):e28385. doi: 10.1016/j.heliyon.2024.e28385. eCollection 2024 Apr 15.

Authors

Francesca Matilde Schipilliti¹, Denise Drittone¹, Federica Mazzuca², Daniele La Forgia³, Deniz Can Guven⁴, Alessandro Rizzo³

Affiliations

¹ Oncological Department, Sant'Andrea Hospital, University Sapienza in Rome, Rome, Italy.
² Department of Clinical and Molecular Medicine, Sapienza University, Oncology Unit, Azienda Ospedialiera Universitaria Sant'Andrea, Rome, Italy.
³ IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
⁴ Department of Medical Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey.

Abstract

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.

Keywords: ADC; Antibody-drug conjugates; Breast cancer; Dato-DXd; Datopotamab deruxtecan; Triple-negative breast cancer.